Form 4: Jazz Pharmaceuticals Executive Acquires Shares Following Performance Vesting
SEC Form 4
Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals, acquired 1,641 ordinary shares following the vesting of performance-based awards.
Summary
- Patricia Carr, a Senior Vice President and Chief Accounting Officer at Jazz Pharmaceuticals, acquired 1,641 ordinary shares.
- The shares were acquired as a result of performance share awards granted on March 3, 2022.
- The performance-based vesting requirements for these awards were met on January 17, 2025.
- The vesting was certified on January 17, 2025, triggering the delivery of the shares.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation. The vesting of performance shares suggests that performance goals were met, which is a positive sign. However, it is not a major event that would significantly impact the company's outlook.
Positives
- The vesting of performance shares indicates that performance goals were met.
- The acquisition of shares by a key executive can be seen as a positive sign of confidence in the company.
Industry Context
This is a standard transaction related to executive compensation in publicly traded companies. Performance-based equity awards are common to align executive interests with company performance.
Comparison to Industry Standards
- Performance-based equity awards are a common practice in the pharmaceutical industry, used to incentivize executives and align their interests with shareholder value.
- Many companies, such as Amgen, Gilead Sciences, and Biogen, use similar equity-based compensation plans for their executives.
- The vesting of these awards is typically tied to specific performance metrics, such as revenue growth, profitability, or clinical trial milestones.
Stakeholder Impact
- The share acquisition by a key executive could be viewed positively by shareholders, indicating confidence in the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/03/2022 | Date of the performance share awards made to Patricia Carr. |
| 01/17/2025 | Date the performance-based vesting requirements were satisfied and certified. |
| 01/22/2025 | Date of signature of the report. |
Keywords
Jazz Pharmaceuticals, share acquisition, performance shares, executive compensation, insider trading, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.